News headlines about Bioline RX (NASDAQ:BLRX) have trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioline RX earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 47.4321581569253 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Bioline RX from a “sell” rating to a “hold” rating in a research report on Tuesday, February 20th. HC Wainwright set a $4.00 price objective on shares of Bioline RX and gave the company a “buy” rating in a report on Wednesday, January 17th. ValuEngine upgraded shares of Bioline RX from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Maxim Group set a $3.00 price objective on shares of Bioline RX and gave the company a “buy” rating in a report on Monday, December 4th. Finally, Oppenheimer set a $3.00 price objective on shares of Bioline RX and gave the company a “buy” rating in a report on Monday, December 4th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $2.85.
Shares of Bioline RX (NASDAQ BLRX) traded up $0.01 during midday trading on Tuesday, reaching $0.96. 23,665 shares of the company traded hands, compared to its average volume of 565,228. Bioline RX has a fifty-two week low of $0.80 and a fifty-two week high of $1.34. The firm has a market capitalization of $102.57, a price-to-earnings ratio of -3.54 and a beta of 0.15.
Bioline RX (NASDAQ:BLRX) last announced its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.01). equities research analysts expect that Bioline RX will post -0.31 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Bioline RX (BLRX) Receiving Somewhat Favorable Media Coverage, Analysis Finds” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/20/bioline-rx-blrx-receiving-somewhat-favorable-media-coverage-analysis-finds.html.
Bioline RX Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.